Get Support

Search global stocks & ETFs...Ctrl K

Learn Mode

VRTX - Vertex Pharmaceuticals Inc

330

$436.95

-$13.46 (-2.988%)

At market close

$437.87

$0.92 (0.211%)

After Hours 5/15/26, 11:53 PM

3.88/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

VRTX

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$110.90B

Industry

Biotechnology

EPS (TTM)

$16.92

P/E (TTM)

25.56

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

9.08

P/B

5.73

Diluted Shares

256.30M

Ex-Dividend

--

Next Earnings

08-03

Forward P/E

21.99

Payout Ratio

--

P/FCF (TTM)

29.89

FCF Yield

3.35%

Earnings Yield

3.91%

52 Week Range

Score Card

Explore Scores Tab

3.88

Good

Vertex Pharmaceuticals Inc has grown revenue at 10.08% over the past year, which is strong growth. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

4.00

Good

Management

2.00

Bad

Growth

3.00

Average

Profitability

4.00

Good

Fin. Health

5.00

Very Good

Dividends

--

--

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

15 new filings were in the last 7 days

Filter Form Types

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-15 10:41:01

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-15 10:02:02

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-14 16:10:04

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-05-14 13:55:35

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-05-14 10:19:20

Form S-8 POS

Securities to be offered to employees in employee benefit plans, post-effective amendments

Filed on 2026-05-13 16:10:21

Form S-8 POS

Securities to be offered to employees in employee benefit plans, post-effective amendments

Filed on 2026-05-13 16:10:16

Form S-8 POS

Securities to be offered to employees in employee benefit plans, post-effective amendments

Filed on 2026-05-13 16:10:11

Form S-8 POS

Securities to be offered to employees in employee benefit plans, post-effective amendments

Filed on 2026-05-13 16:10:03

Form S-8 POS

Securities to be offered to employees in employee benefit plans, post-effective amendments

Filed on 2026-05-13 16:09:57

Form S-8 POS

Securities to be offered to employees in employee benefit plans, post-effective amendments

Filed on 2026-05-13 16:09:52

Form S-8 POS

Securities to be offered to employees in employee benefit plans, post-effective amendments

Filed on 2026-05-13 16:09:46

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$673.05

54.0%

Avg:

$558.61

27.8%

Low:

$333.30

-23.7%

(% change is relative to the current stock price: $436.95)

Analyst Recommendations

Go to Analyst Tab

4.10

Good

33%

Strong Buy (13)

49%

Buy (19)

15%

Hold (6)

0%

Sell (0)

3%

Strong Sell (1)

About

Website
https://www.vrtx.com/
Address
50 Northern Avenue, Boston MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=875320

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

IPO Date

1991-07-24

Industry

Biotechnology

Total Employees

6,400

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences